The global Viral Vectors and Plasmid DNA Manufacturing market size was valued at US$ 869 million in 2024 and is forecast to a readjusted size of USD 2668 million by 2031 with a CAGR of 17.6% during review period.
The viral vectors and plasmid DNA is used for the treatment of cancers, inherited disorders, viral infections and other diseases.
Global Viral Vectors and Plasmid DNA Manufacturing key players include BioReliance, Oxford BioMedica, UniQure, Cobra Biologics, etc. Global top four manufacturers hold a share over 45%.
North America is the largest market, with a share about 50%, followed by Asia-Pacific, and Europe, both have a share over 40 percent.
In terms of product, Viral Vectors is the largest segment, with a share about 80%. And in terms of application, the largest application is Cancers, followed by Inherited Disorders, Viral Infections , etc.
This report is a detailed and comprehensive analysis for global Viral Vectors and Plasmid DNA Manufacturing market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Viral Vectors and Plasmid DNA Manufacturing market size and forecasts, in consumption value ($ Million), 2020-2031
Global Viral Vectors and Plasmid DNA Manufacturing market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Viral Vectors and Plasmid DNA Manufacturing market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global Viral Vectors and Plasmid DNA Manufacturing market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Viral Vectors and Plasmid DNA Manufacturing
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Viral Vectors and Plasmid DNA Manufacturing market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include BioReliance, Cobra Biologics, Oxford BioMedica, UniQure, FinVector, MolMed, MassBiologics, Richter-Helm, FUJIFILM Diosynth Biotechnologies, Lonza, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 segmentation
Viral Vectors and Plasmid DNA Manufacturing market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
Plasmid DNA
Viral Vectors
麻豆原创 segment by Application
Cancers
Inherited Disorders
Viral Infections
Others
麻豆原创 segment by players, this report covers
BioReliance
Cobra Biologics
Oxford BioMedica
UniQure
FinVector
MolMed
MassBiologics
Richter-Helm
FUJIFILM Diosynth Biotechnologies
Lonza
Aldevron
Eurogentec
Cell and Gene Therapy Catapult
Biovian
Thermo Fisher Scientific (Brammer Bio)
VGXI
PlasmidFactory
麻豆原创 segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Viral Vectors and Plasmid DNA Manufacturing product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Viral Vectors and Plasmid DNA Manufacturing, with revenue, gross margin, and global market share of Viral Vectors and Plasmid DNA Manufacturing from 2020 to 2025.
Chapter 3, the Viral Vectors and Plasmid DNA Manufacturing competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Viral Vectors and Plasmid DNA Manufacturing market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Viral Vectors and Plasmid DNA Manufacturing.
Chapter 13, to describe Viral Vectors and Plasmid DNA Manufacturing research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 Classification of Viral Vectors and Plasmid DNA Manufacturing by Type
1.3.1 Overview: Global Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Size by Type: 2020 Versus 2024 Versus 2031
1.3.2 Global Viral Vectors and Plasmid DNA Manufacturing Consumption Value 麻豆原创 Share by Type in 2024
1.3.3 Plasmid DNA
1.3.4 Viral Vectors
1.4 Global Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 by Application
1.4.1 Overview: Global Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Size by Application: 2020 Versus 2024 Versus 2031
1.4.2 Cancers
1.4.3 Inherited Disorders
1.4.4 Viral Infections
1.4.5 Others
1.5 Global Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Size & Forecast
1.6 Global Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Size and Forecast by Region
1.6.1 Global Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
1.6.2 Global Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Size by Region, (2020-2031)
1.6.3 North America Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Size and Prospect (2020-2031)
1.6.4 Europe Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Size and Prospect (2020-2031)
1.6.5 Asia-Pacific Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Size and Prospect (2020-2031)
1.6.6 South America Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Size and Prospect (2020-2031)
1.6.7 Middle East & Africa Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Size and Prospect (2020-2031)
2 Company Profiles
2.1 BioReliance
2.1.1 BioReliance Details
2.1.2 BioReliance Major Business
2.1.3 BioReliance Viral Vectors and Plasmid DNA Manufacturing Product and Solutions
2.1.4 BioReliance Viral Vectors and Plasmid DNA Manufacturing Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.1.5 BioReliance Recent Developments and Future Plans
2.2 Cobra Biologics
2.2.1 Cobra Biologics Details
2.2.2 Cobra Biologics Major Business
2.2.3 Cobra Biologics Viral Vectors and Plasmid DNA Manufacturing Product and Solutions
2.2.4 Cobra Biologics Viral Vectors and Plasmid DNA Manufacturing Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.2.5 Cobra Biologics Recent Developments and Future Plans
2.3 Oxford BioMedica
2.3.1 Oxford BioMedica Details
2.3.2 Oxford BioMedica Major Business
2.3.3 Oxford BioMedica Viral Vectors and Plasmid DNA Manufacturing Product and Solutions
2.3.4 Oxford BioMedica Viral Vectors and Plasmid DNA Manufacturing Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.3.5 Oxford BioMedica Recent Developments and Future Plans
2.4 UniQure
2.4.1 UniQure Details
2.4.2 UniQure Major Business
2.4.3 UniQure Viral Vectors and Plasmid DNA Manufacturing Product and Solutions
2.4.4 UniQure Viral Vectors and Plasmid DNA Manufacturing Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.4.5 UniQure Recent Developments and Future Plans
2.5 FinVector
2.5.1 FinVector Details
2.5.2 FinVector Major Business
2.5.3 FinVector Viral Vectors and Plasmid DNA Manufacturing Product and Solutions
2.5.4 FinVector Viral Vectors and Plasmid DNA Manufacturing Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.5.5 FinVector Recent Developments and Future Plans
2.6 MolMed
2.6.1 MolMed Details
2.6.2 MolMed Major Business
2.6.3 MolMed Viral Vectors and Plasmid DNA Manufacturing Product and Solutions
2.6.4 MolMed Viral Vectors and Plasmid DNA Manufacturing Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.6.5 MolMed Recent Developments and Future Plans
2.7 MassBiologics
2.7.1 MassBiologics Details
2.7.2 MassBiologics Major Business
2.7.3 MassBiologics Viral Vectors and Plasmid DNA Manufacturing Product and Solutions
2.7.4 MassBiologics Viral Vectors and Plasmid DNA Manufacturing Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.7.5 MassBiologics Recent Developments and Future Plans
2.8 Richter-Helm
2.8.1 Richter-Helm Details
2.8.2 Richter-Helm Major Business
2.8.3 Richter-Helm Viral Vectors and Plasmid DNA Manufacturing Product and Solutions
2.8.4 Richter-Helm Viral Vectors and Plasmid DNA Manufacturing Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.8.5 Richter-Helm Recent Developments and Future Plans
2.9 FUJIFILM Diosynth Biotechnologies
2.9.1 FUJIFILM Diosynth Biotechnologies Details
2.9.2 FUJIFILM Diosynth Biotechnologies Major Business
2.9.3 FUJIFILM Diosynth Biotechnologies Viral Vectors and Plasmid DNA Manufacturing Product and Solutions
2.9.4 FUJIFILM Diosynth Biotechnologies Viral Vectors and Plasmid DNA Manufacturing Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.9.5 FUJIFILM Diosynth Biotechnologies Recent Developments and Future Plans
2.10 Lonza
2.10.1 Lonza Details
2.10.2 Lonza Major Business
2.10.3 Lonza Viral Vectors and Plasmid DNA Manufacturing Product and Solutions
2.10.4 Lonza Viral Vectors and Plasmid DNA Manufacturing Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.10.5 Lonza Recent Developments and Future Plans
2.11 Aldevron
2.11.1 Aldevron Details
2.11.2 Aldevron Major Business
2.11.3 Aldevron Viral Vectors and Plasmid DNA Manufacturing Product and Solutions
2.11.4 Aldevron Viral Vectors and Plasmid DNA Manufacturing Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.11.5 Aldevron Recent Developments and Future Plans
2.12 Eurogentec
2.12.1 Eurogentec Details
2.12.2 Eurogentec Major Business
2.12.3 Eurogentec Viral Vectors and Plasmid DNA Manufacturing Product and Solutions
2.12.4 Eurogentec Viral Vectors and Plasmid DNA Manufacturing Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.12.5 Eurogentec Recent Developments and Future Plans
2.13 Cell and Gene Therapy Catapult
2.13.1 Cell and Gene Therapy Catapult Details
2.13.2 Cell and Gene Therapy Catapult Major Business
2.13.3 Cell and Gene Therapy Catapult Viral Vectors and Plasmid DNA Manufacturing Product and Solutions
2.13.4 Cell and Gene Therapy Catapult Viral Vectors and Plasmid DNA Manufacturing Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.13.5 Cell and Gene Therapy Catapult Recent Developments and Future Plans
2.14 Biovian
2.14.1 Biovian Details
2.14.2 Biovian Major Business
2.14.3 Biovian Viral Vectors and Plasmid DNA Manufacturing Product and Solutions
2.14.4 Biovian Viral Vectors and Plasmid DNA Manufacturing Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.14.5 Biovian Recent Developments and Future Plans
2.15 Thermo Fisher Scientific (Brammer Bio)
2.15.1 Thermo Fisher Scientific (Brammer Bio) Details
2.15.2 Thermo Fisher Scientific (Brammer Bio) Major Business
2.15.3 Thermo Fisher Scientific (Brammer Bio) Viral Vectors and Plasmid DNA Manufacturing Product and Solutions
2.15.4 Thermo Fisher Scientific (Brammer Bio) Viral Vectors and Plasmid DNA Manufacturing Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.15.5 Thermo Fisher Scientific (Brammer Bio) Recent Developments and Future Plans
2.16 VGXI
2.16.1 VGXI Details
2.16.2 VGXI Major Business
2.16.3 VGXI Viral Vectors and Plasmid DNA Manufacturing Product and Solutions
2.16.4 VGXI Viral Vectors and Plasmid DNA Manufacturing Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.16.5 VGXI Recent Developments and Future Plans
2.17 PlasmidFactory
2.17.1 PlasmidFactory Details
2.17.2 PlasmidFactory Major Business
2.17.3 PlasmidFactory Viral Vectors and Plasmid DNA Manufacturing Product and Solutions
2.17.4 PlasmidFactory Viral Vectors and Plasmid DNA Manufacturing Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.17.5 PlasmidFactory Recent Developments and Future Plans
3 麻豆原创 Competition, by Players
3.1 Global Viral Vectors and Plasmid DNA Manufacturing Revenue and Share by Players (2020-2025)
3.2 麻豆原创 Share Analysis (2024)
3.2.1 麻豆原创 Share of Viral Vectors and Plasmid DNA Manufacturing by Company Revenue
3.2.2 Top 3 Viral Vectors and Plasmid DNA Manufacturing Players 麻豆原创 Share in 2024
3.2.3 Top 6 Viral Vectors and Plasmid DNA Manufacturing Players 麻豆原创 Share in 2024
3.3 Viral Vectors and Plasmid DNA Manufacturing 麻豆原创: Overall Company Footprint Analysis
3.3.1 Viral Vectors and Plasmid DNA Manufacturing 麻豆原创: Region Footprint
3.3.2 Viral Vectors and Plasmid DNA Manufacturing 麻豆原创: Company Product Type Footprint
3.3.3 Viral Vectors and Plasmid DNA Manufacturing 麻豆原创: Company Product Application Footprint
3.4 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 麻豆原创 Size Segment by Type
4.1 Global Viral Vectors and Plasmid DNA Manufacturing Consumption Value and 麻豆原创 Share by Type (2020-2025)
4.2 Global Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Forecast by Type (2026-2031)
5 麻豆原创 Size Segment by Application
5.1 Global Viral Vectors and Plasmid DNA Manufacturing Consumption Value 麻豆原创 Share by Application (2020-2025)
5.2 Global Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Forecast by Application (2026-2031)
6 North America
6.1 North America Viral Vectors and Plasmid DNA Manufacturing Consumption Value by Type (2020-2031)
6.2 North America Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Size by Application (2020-2031)
6.3 North America Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Size by Country
6.3.1 North America Viral Vectors and Plasmid DNA Manufacturing Consumption Value by Country (2020-2031)
6.3.2 United States Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Size and Forecast (2020-2031)
6.3.3 Canada Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Size and Forecast (2020-2031)
6.3.4 Mexico Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Size and Forecast (2020-2031)
7 Europe
7.1 Europe Viral Vectors and Plasmid DNA Manufacturing Consumption Value by Type (2020-2031)
7.2 Europe Viral Vectors and Plasmid DNA Manufacturing Consumption Value by Application (2020-2031)
7.3 Europe Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Size by Country
7.3.1 Europe Viral Vectors and Plasmid DNA Manufacturing Consumption Value by Country (2020-2031)
7.3.2 Germany Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Size and Forecast (2020-2031)
7.3.3 France Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Size and Forecast (2020-2031)
7.3.4 United Kingdom Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Size and Forecast (2020-2031)
7.3.5 Russia Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Size and Forecast (2020-2031)
7.3.6 Italy Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Size and Forecast (2020-2031)
8 Asia-Pacific
8.1 Asia-Pacific Viral Vectors and Plasmid DNA Manufacturing Consumption Value by Type (2020-2031)
8.2 Asia-Pacific Viral Vectors and Plasmid DNA Manufacturing Consumption Value by Application (2020-2031)
8.3 Asia-Pacific Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Size by Region
8.3.1 Asia-Pacific Viral Vectors and Plasmid DNA Manufacturing Consumption Value by Region (2020-2031)
8.3.2 China Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Size and Forecast (2020-2031)
8.3.3 Japan Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Size and Forecast (2020-2031)
8.3.4 South Korea Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Size and Forecast (2020-2031)
8.3.5 India Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Size and Forecast (2020-2031)
8.3.6 Southeast Asia Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Size and Forecast (2020-2031)
8.3.7 Australia Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Size and Forecast (2020-2031)
9 South America
9.1 South America Viral Vectors and Plasmid DNA Manufacturing Consumption Value by Type (2020-2031)
9.2 South America Viral Vectors and Plasmid DNA Manufacturing Consumption Value by Application (2020-2031)
9.3 South America Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Size by Country
9.3.1 South America Viral Vectors and Plasmid DNA Manufacturing Consumption Value by Country (2020-2031)
9.3.2 Brazil Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Size and Forecast (2020-2031)
9.3.3 Argentina Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Size and Forecast (2020-2031)
10 Middle East & Africa
10.1 Middle East & Africa Viral Vectors and Plasmid DNA Manufacturing Consumption Value by Type (2020-2031)
10.2 Middle East & Africa Viral Vectors and Plasmid DNA Manufacturing Consumption Value by Application (2020-2031)
10.3 Middle East & Africa Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Size by Country
10.3.1 Middle East & Africa Viral Vectors and Plasmid DNA Manufacturing Consumption Value by Country (2020-2031)
10.3.2 Turkey Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Size and Forecast (2020-2031)
10.3.3 Saudi Arabia Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Size and Forecast (2020-2031)
10.3.4 UAE Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Size and Forecast (2020-2031)
11 麻豆原创 Dynamics
11.1 Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Drivers
11.2 Viral Vectors and Plasmid DNA Manufacturing 麻豆原创 Restraints
11.3 Viral Vectors and Plasmid DNA Manufacturing Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 Viral Vectors and Plasmid DNA Manufacturing Industry Chain
12.2 Viral Vectors and Plasmid DNA Manufacturing Upstream Analysis
12.3 Viral Vectors and Plasmid DNA Manufacturing Midstream Analysis
12.4 Viral Vectors and Plasmid DNA Manufacturing Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
BioReliance
Cobra Biologics
Oxford BioMedica
UniQure
FinVector
MolMed
MassBiologics
Richter-Helm
FUJIFILM Diosynth Biotechnologies
Lonza
Aldevron
Eurogentec
Cell and Gene Therapy Catapult
Biovian
Thermo Fisher Scientific (Brammer Bio)
VGXI
PlasmidFactory
听
听
*If Applicable.
